On July 7, ResMed rose 5.01% in regular trading, trading at $220.57/share, with turnover of $433 million. The rally was driven by a combination of strategic acquisition momentum and upcoming earnings expectations.

On the news front, ResMed recently completed its $340 million all-cash acquisition of Noctrix Health, a medical device company developing wearable therapeutics for chronic neurological disorders. The deal brings Noctrix's FDA De Novo classified Nidra TOMAC Therapy — a nonpharmacologic treatment for moderate-to-severe Restless Legs Syndrome — into ResMed's clinical sleep health portfolio. RLS is the third most prevalent sleep disorder, and the therapy will be integrated into ResMed's global ecosystem of over 27 million cloud-connected devices, creating significant commercial synergies.

Additionally, the company announced it will release fiscal Q4 results on August 6, with consensus EPS estimates at $2.9. The stock had previously traded near its 52-week low following a Morgan Stanley downgrade to equal-weight but is now showing a clear recovery pattern. For context, ResMed beat Q2 estimates with non-GAAP EPS of $2.81 versus the $2.72 consensus, on revenue of $1.42 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)